Shuanglong Xiong1†
Chengxiang Yang1†
Kaiwen Fu1Xingyun Liao1
Yao Ding1Kexue Zhou1
Li Zhang1Yan Teng1Chunman Wu2Yongsheng Li1*Houjie Liang3*Yan Li1*- 1Department of Oncology, Chongqing University Cancer Hospital, Chongqing, China
- 2Nanjing Geneseeq Technology Inc, Nanjing, China
- 3Department of Oncology and Southwest Cancer Centre, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China
By Xiong S, Yang C, Fu K, Liao X, Ding Y, Zhou K, Zhang L, Teng Y, Wu C, Li Y, Liang H and Li Y (2025) Front. Oncol. 15:1527719. doi: 10.3389/fonc.2025.1527719
Author “Chunman Wu” was erroneously assigned to affiliation “Chongqing University Cancer Hospital”. This affiliation has now been removed for author “Chunman Wu”.
Affiliation “Nanjing Geneseeq Technology Inc, Nanjing, China” was omitted for author “Chunman Wu”. This affiliation has now been added for author “Chunman Wu”. Shuanglong Xiong1†, Chengxiang Yang1†, Kaiwen Fu1, Xingyun Liao1, Yao Ding1, Kexue Zhou1, Li Zhang1, Yan Teng1, Chunman Wu2, Yongsheng Li1*, Houjie Liang3* and Yan Li1*
1Department of Oncology, Chongqing University Cancer Hospital, Chongqing, China, 2Nanjing Geneseeq Technology Inc, Nanjing, China, 3Department of Oncology and Southwest Cancer Centre, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
The Conflict of interest statement has been correct to “Author CW was employed by Nanjing Geneseeq Technology Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.”
The funder “1. Beijing Xisike Clinical Oncology Research Foundation (Y-HH202102-0200); 2. Senior Medical Talents Program of Chongqing for Young and Middle-aged (2020GDRC005)” were erroneously omitted.
The original version of this article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: lung large-cell neuroendocrine carcinoma, Surufatinib, toripalimab, immune microenvironment, TMB
Citation: Xiong S, Yang C, Fu K, Liao X, Ding Y, Zhou K, Zhang L, Teng Y, Wu C, Li Y, Liang H and Li Y (2025) Correction: Case Report: Curative effect and mechanism of surufatinib combined with toripalimab in the treatment of 1 case of lung large-cell neuroendocrine carcinoma. Front. Oncol. 15:1730518. doi: 10.3389/fonc.2025.1730518
Received: 22 October 2025; Accepted: 06 November 2025; Revised: 28 October 2025;
Published: 18 November 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Xiong, Yang, Fu, Liao, Ding, Zhou, Zhang, Teng, Wu, Li, Liang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yongsheng Li, eW9uZ3NoZW5nbGkyMDA1QDE2My5jb20=; Yan Li, cGlwaWxpQHNpbmEuY29t; Houjie Liang, bGlhbmdob3VqaWVfMTI1OUBzaW5hLmNvbQ==
†These authors have contributed equally to this work